Electrocatalysis for the synthesis of chiral and PET imaging pharmaceuticals
电催化合成手性和 PET 成像药物
基本信息
- 批准号:10681378
- 负责人:
- 金额:$ 24.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AlkenesAmidesAminesAmino AcidsCarbon DioxideCarboxylic AcidsCatalysisCell NucleusChemicalsCobaltCollaborationsComplexCouplingData ScienceDetectionDevelopmentElectricityElectrochemistryElectrodesElectrolysesElectrolytesElectronsExcisionGoalsGrantLabelLigandsMedicalMentorsMethodsModificationNitrilesOpticsOrganic ChemistryOrganic SynthesisOrganometallic ChemistryOxidantsPathway interactionsPatientsPeptidesPharmaceutical PreparationsPharmacologic SubstancePhasePhysiologic pulsePositron-Emission TomographyPreparationProcessProlineRadioactiveRadioactive ElementsRadioactivityRadioisotopesRadiolabeledRadiopharmaceuticalsReactionReaction TimeReagentReducing AgentsResearchSeriesSolidSystemTechniquesTemperatureTimeTracerTransition ElementsWorkbioimagingcarboxylatecarboxylationcatalystchemical reactionchiral moleculedesigndisorder preventiondrug discoveryfunctional groupimaging agentimprovedinterdisciplinary approachmarinenovelnovel strategiespeptide synthasepolypeptidepreventprogramstoxic metal
项目摘要
Project Summary/Abstract
Chiral drugs and radiolabelled compounds are two general classes of highly sought molecules for the
detection, treatment, and prevention of disease. Chiral compounds are present in the majority of complex
bioactive drugs. On the other hand, radiolabeled compounds are widely used as imaging agents for positron
emission tomography (PET). Despite the many recent advancements in synthetic organic chemistry, such
as in transition-metal (TM) catalysis, the incorporation of functional groups to construct stereogenic centers
and/or install radioactive nuclei in a safe and sustainable method remains challenging. Thus, providing
opportunities to develop novel approaches in organic synthesis relevant to drug discovery. Electrosyntheses
have shown application in organic synthesis; however, it suffers from achieving product selectivity and lacks
the ability to construct stereogenic centers.
The overall goal of this project is to integrate electrochemistry and transition-metal catalysis to provide
solutions on the challenges in organic synthesis particularly in the assembly of chiral and radiolabeled drugs.
This grant builds on existing collaboration between the Minteer Lab (electrocatalysis, electroanalysis) and
the Sigman Lab (asymmetric catalysis, data science) in the development of electroactive compounds for
battery and synthesis applications. Integration of my expertise (organic chemistry, transition metal catalysis,
and organometallic chemistry) with Minteer and Sigman will bring a collective capability to accomplish the
overall goal. The central hypothesis of this application is that through the use of electrochemical energy,
non-toxic TM can be used as electrocatalysts to selectively install functional groups/atoms that are often
used as radioactive elements in PET tracers while generating a stereogenic center. Specifically, we will (Aim
1) develop cobalt electrocatalytic asymmetric reactions to convert organohalides into chiral carboxylic acids,
nitriles, and fluorinated compounds. This electrocatalytic approach will also allow us to discover new
reactions that are valuable in medical applications. Through catalyst design and electroanalysis, we will
develop (Aim 2) TM-electrocatalysts capable of activating and functionalizing inert amide bonds (most
represented polar bond in organic and biomolecules). This will provide a late-stage functionalization in
amide-containing marine products and polypeptides. Radiopharmaceuticals for PET imaging require rapid
preparation and delivery to patients due to their short-lived radioactivity (t1/2 = 20.4 and 110 min for 11C and
18F radionuclide, respectively). For the first time, we will use the strategic merger of electrochemistry and
TM-catalysis to provide a new synthetic approach to deliver chiral radiopharmaceuticals (Aim 3). The
transformations in Aims 1 and 2 were carefully chosen based on their high potential to be adapted for the
assembly of radiopharmaceuticals. Overall, this project will deliver unique, organic transformations that will
directly impact the complex process of drug discovery.
项目摘要/摘要
手性药物和放射性标记化合物是两大类备受关注的分子
疾病的检测、治疗和预防。手性化合物存在于大多数络合物中。
生物活性药物。另一方面,放射性标记化合物被广泛用作正电子显像剂。
发射断层扫描(PET)。尽管合成有机化学最近取得了许多进展,但
在过渡金属(TM)催化中,官能团的结合以构建立体生成中心
和/或以安全和可持续的方法安装放射性核仍然具有挑战性。因此,提供
开发与药物发现相关的有机合成新方法的机会。电合成
已经显示出在有机合成中的应用;然而,它在实现产品选择性方面存在缺陷,并且缺乏
构建立体中心的能力。
该项目的总体目标是将电化学和过渡金属催化相结合,以提供
解决有机合成中的挑战,特别是手性药物和放射性标记药物的组装。
这笔赠款建立在Minteer实验室(电催化、电分析)和
西格曼实验室(不对称催化,数据科学)在开发电活性化合物方面的作用
电池和合成应用。整合我的专业知识(有机化学、过渡金属催化、
和有机金属化学)与Minteer和Sigman合作将带来集体能力来完成
总体目标。这一应用的中心假设是通过使用电化学能量,
无毒的TM可用作电催化剂,选择性地安装经常
在PET示踪剂中用作放射性元素,同时产生立体中心。具体地说,我们将(瞄准
1)发展钴电催化不对称反应,将有机卤化物转化为手性羧酸,
氰化物和含氟化合物。这种电催化方法还将使我们能够发现新的
在医学应用中有价值的反应。通过催化剂设计和电分析,我们将
开发(目标2)TM-能够活化和功能化惰性酰胺键(MOST)的电催化剂
代表有机和生物分子中的极性键)。这将在以下方面提供后期功能
含酰胺的海产品和多肽。用于PET成像的放射性药物需要快速
由于放射性寿命短而准备和交付给患者(T1/2=20.4和11C和110min
18F放射性核素)。我们将首次使用电化学和化学的战略合并
TM-催化提供了一种新的合成方法来传递手性放射性药物(目标3)。这个
AIMS 1和AIMS 2中的转换是根据它们的高潜力精心选择的,以适应
放射性药物的组装。总体而言,该项目将提供独特的、有机的转型,
直接影响着复杂的药物发现过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christian Malapit其他文献
Christian Malapit的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christian Malapit', 18)}}的其他基金
Electrocatalysis for the synthesis of chiral and PET imaging pharmaceuticals
电催化合成手性和 PET 成像药物
- 批准号:
10661909 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
相似海外基金
Collaborative Research: NSF-DFG: CAS: Electrochemical Hydrogenation of Amides and Esters
合作研究:NSF-DFG:CAS:酰胺和酯的电化学氢化
- 批准号:
2140205 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
Collaborative Research: NSF-DFG: CAS: Electrochemical Hydrogenation of Amides and Esters
合作研究:NSF-DFG:CAS:酰胺和酯的电化学氢化
- 批准号:
2140196 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Standard Grant
Atroposelective Synthesis of Hindered Amides - Exploration of Synthetic Peptide Catalysts -
受阻酰胺的天体选择性合成-合成肽催化剂的探索-
- 批准号:
504378162 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
WBP Fellowship
Development of Peptide Chemical Modification Enabled by N-Halogenation of Amides
酰胺 N-卤化实现的肽化学修饰的发展
- 批准号:
22H02743 - 财政年份:2022
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Modulating Signaling Endocannabinoids and Fatty Acid Amides
调节信号传导内源性大麻素和脂肪酸酰胺
- 批准号:
10532252 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
CAREER: SusChEM: Iron Catalysts for the Reduction of Amides
职业:SusChEM:用于还原酰胺的铁催化剂
- 批准号:
2146728 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Continuing Grant
Modulating Signaling Endocannabinoids and Fatty Acid Amides
调节信号传导内源性大麻素和脂肪酸酰胺
- 批准号:
10399712 - 财政年份:2021
- 资助金额:
$ 24.9万 - 项目类别:
Nickel-Catalyzed Alpha-Arylation of Secondary Amides
镍催化仲酰胺的α-芳基化
- 批准号:
558383-2020 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Canadian Graduate Scholarships Foreign Study Supplements
Function of primary fatty acid amides as lipid mediators
伯脂肪酸酰胺作为脂质介质的功能
- 批准号:
20K21285 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Improving selectivity in Ni-catalyzed activation of amides
提高镍催化酰胺活化的选择性
- 批准号:
518319-2018 - 财政年份:2020
- 资助金额:
$ 24.9万 - 项目类别:
Postgraduate Scholarships - Doctoral